EMV Capital (AIM:EMVC) CEO Dr Ilian Iliev and Tom Smith, CEO of EMV portfolio company Wanda Health, talked with Proactive's Stephen Gunnion about how the company is transforming virtual care for cardiometabolic diseases and weight management. Smith said Wanda has developed a new care model that integrates intelligent technology, connected devices, and coaching to deliver better patient outcomes and reduce dependence on expensive medications like GLP-1s. "We built a new model of virtual care designed specifically for cardiometabolic disease and weight management, areas where traditional medication-driven approaches have become too expensive and all too far reactive," Smith explained. He added that the company’s platform is gaining strong traction in the US healthcare market, particularly with health plans seeking to cut GLP-1 costs and improve chronic disease outcomes. Smith highlighted that the company’s strongest momentum is with US health plans, large employers, and chronic care providers. In 2025, Wanda launched a GLP-1 management program, scaled its coaching services, and released an insights engine for population health intelligence. Over the next 12 to 18 months, key revenue drivers are expected to include the expansion of GLP-1 cost-reduction programs, broader chronic disease pathways, and commercialisation of its analytics tools. Iliev noted that Wanda aligns with EMV's "Venture Build" program, emphasising its IP, real-world healthcare impact, and the adaptability of its business model. For more exclusive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future updates. #DigitalHealth #VirtualCare #GLP1 #CardiometabolicHealth #WandaHealth #ChronicDisease #HealthTech #RemoteMonitoring #WeightManagement #USHealthcare #EMVCapital #HealthInnovation
